Roivant sets price for new rare disease drug Lisraya at $35,000 a month
28/08/2026 13:13
Roivant sets price for new rare disease drug Lisraya at $35,000 a month Aug 28 (Reuters) - Roivant ROIV.O and partner Priovant Therapeutics' newly approved rare disease drug Lisraya will carry a list price of $35,000 for a 30-day supply, Roivant Chief Executive Matt Gline said on an analyst call on Friday.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)
Recent news on Roivant Sciences
See all newsU.S. STOCKS ON THE MOVE-Thermo Fisher, CME, Capital One, Northern Trust
Roivant rises as drug succeeds in two late-stage trials for eye disease
Immunovant falls after lupus drug setback
Brief: Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple